Penumbra Current Ratio Growth & History (PEN)
Penumbra's current ratio was 6.64 for fiscal 2025.
View full Penumbra company overviewPenumbra annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 6.64 | 0.64 | +10.61% |
| 2024 | 2024-12-31 | 6.01 | −0.05 | −0.82% |
| 2023 | 2023-12-31 | 6.06 | 0.84 | +16.15% |
| 2022 | 2022-12-31 | 5.21 | −0.32 | −5.74% |
| 2021 | 2021-12-31 | 5.53 | −0.30 | −5.14% |
| 2020 | 2020-12-31 | 5.83 | 0.74 | +14.63% |
| 2019 | 2019-12-31 | 5.09 | −1.13 | −18.18% |
| 2018 | 2018-12-31 | 6.22 | −1.19 | −16.10% |
| 2017 | 2017-12-31 | 7.41 | 0.04 | +0.55% |
| 2016 | 2016-12-31 | 7.37 | −1.31 | −15.11% |
| 2015 | 2015-12-31 | 8.68 | 3.14 | +56.78% |
| 2014 | 2014-12-31 | 5.54 | — | — |
Penumbra quarterly current ratio
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 5.75 | −1.00 | −14.87% |
| Q1 2026 | 2026-03-31 | 6.02 | −0.28 | −4.42% |
| Q4 2025 | 2025-12-31 | 6.64 | 0.64 | +10.61% |
| Q3 2025 | 2025-09-30 | 6.73 | 0.91 | +15.62% |
| Q2 2025 | 2025-06-30 | 6.75 | 0.50 | +8.05% |
| Q1 2025 | 2025-03-31 | 6.30 | 0.18 | +2.99% |
| Q4 2024 | 2024-12-31 | 6.01 | −0.05 | −0.82% |
| Q3 2024 | 2024-09-30 | 5.82 | −0.16 | −2.75% |
| Q2 2024 | 2024-06-30 | 6.25 | 0.51 | +8.82% |
| Q1 2024 | 2024-03-31 | 6.12 | 0.74 | +13.85% |
| Q4 2023 | 2023-12-31 | 6.06 | 0.84 | +16.15% |
| Q3 2023 | 2023-09-30 | 5.99 | 0.76 | +14.44% |
| Q2 2023 | 2023-06-30 | 5.74 | 0.81 | +16.49% |
| Q1 2023 | 2023-03-31 | 5.37 | 0.07 | +1.29% |
| Q4 2022 | 2022-12-31 | 5.21 | −0.32 | −5.74% |
| Q3 2022 | 2022-09-30 | 5.23 | −0.52 | −9.11% |
| Q2 2022 | 2022-06-30 | 4.93 | — | — |
| Q1 2022 | 2022-03-31 | 5.31 | −0.37 | −6.55% |
| Q4 2021 | 2021-12-31 | 5.53 | −0.30 | −5.14% |
| Q3 2021 | 2021-09-30 | 5.76 | 0.29 | +5.37% |
| Q1 2021 | 2021-03-31 | 5.68 | 0.53 | +10.21% |
| Q4 2020 | 2020-12-31 | 5.83 | 0.74 | +14.63% |
| Q3 2020 | 2020-09-30 | 5.46 | 0.22 | +4.28% |
| Q2 2020 | 2020-06-30 | 7.42 | 1.19 | +19.11% |
| Q1 2020 | 2020-03-31 | 5.15 | −0.94 | −15.48% |
| Q4 2019 | 2019-12-31 | 5.09 | −1.13 | −18.18% |
| Q3 2019 | 2019-09-30 | 5.24 | −0.87 | −14.30% |
| Q2 2019 | 2019-06-30 | 6.23 | −1.67 | −21.13% |
| Q1 2019 | 2019-03-31 | 6.10 | −1.62 | −21.04% |
| Q4 2018 | 2018-12-31 | 6.22 | −1.19 | −16.10% |
| Q3 2018 | 2018-09-30 | 6.11 | −1.17 | −16.03% |
| Q2 2018 | 2018-06-30 | 7.90 | −1.82 | −18.75% |
| Q1 2018 | 2018-03-31 | 7.72 | −1.94 | −20.05% |
| Q4 2017 | 2017-12-31 | 7.41 | 0.04 | +0.55% |
| Q3 2017 | 2017-09-30 | 7.28 | 0.11 | +1.51% |
| Q2 2017 | 2017-06-30 | 9.72 | 1.64 | +20.27% |
| Q1 2017 | 2017-03-31 | 9.66 | 2.19 | +29.35% |
| Q4 2016 | 2016-12-31 | 7.37 | −1.31 | −15.11% |
| Q3 2016 | 2016-09-30 | 7.17 | −1.64 | −18.60% |
| Q2 2016 | 2016-06-30 | 8.08 | — | — |
| Q1 2016 | 2016-03-31 | 7.46 | — | — |
| Q4 2015 | 2015-12-31 | 8.68 | 3.14 | +56.78% |
| Q3 2015 | 2015-09-30 | 8.81 | — | — |
| Q4 2014 | 2014-12-31 | 5.54 | — | — |
Penumbra current ratio trends
Over the last five fiscal years, Penumbra's current ratio increased from 5.83 to 6.64, a change of 0.81. The latest reported quarter, Q2 2026, shows 5.75.
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Penumbra source filings ↗Community posts
Penumbra’s thrombectomy business leads 16% quarterly sales growth
Penumbra ($PEN) reported third-quarter 2026 revenue of $410.1 million, up 15.6%, as demand for its clot-removal systems expanded. Thrombectomy sales increased 18.1% to $279.2 million, including 26% growth in the US venous-thromboembolism bu ...